ONTX
Income statement / Annual
Last year (2023), Onconova Therapeutics, Inc.'s total revenue was $226,000.00,
a decrease of 0.00% from the previous year.
In 2023, Onconova Therapeutics, Inc.'s net income was -$18.95 M.
See Onconova Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$226,000.00
|
$226,000.00
|
$226,000.00
|
$231,000.00
|
$2.18 M
|
$1.23 M
|
$787,000.00
|
$5.55 M
|
$11.46 M
|
$800,000.00
|
| Cost of Revenue |
-$226.00 B |
$14,000.00 |
$14,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$226.00 B |
$212,000.00 |
$212,000.00 |
$231,000.00 |
$2.18 M |
$1.23 M |
$787,000.00 |
$5.55 M |
$11.46 M |
$800,000.00 |
| Gross Profit Ratio |
1000000 |
0.94 |
0.94 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$11.43 M
|
$11.41 M
|
$7.30 M
|
$16.90 M
|
$15.54 M
|
$16.92 M
|
$19.12 M
|
$20.07 M
|
$25.90 M
|
$49.43 M
|
| General & Administrative
Expenses |
$9.09 M
|
$8.45 M
|
$9.43 M
|
$8.33 M
|
$8.35 M
|
$7.59 M
|
$7.41 M
|
$9.18 M
|
$9.53 M
|
$15.12 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$9.09 M
|
$8.45 M
|
$9.43 M
|
$8.33 M
|
$8.35 M
|
$7.59 M
|
$7.41 M
|
$9.18 M
|
$9.53 M
|
$15.12 M
|
| Other Expenses |
$1.35 M |
$663,000.00 |
$12,000.00 |
$48,000.00 |
$143,000.00 |
$1.15 M |
$30,000.00 |
$0.00 |
-$35,000.00 |
-$50,000.00 |
| Operating Expenses |
$20.52 M |
$19.85 M |
$16.72 M |
$25.22 M |
$23.88 M |
$24.51 M |
$26.52 M |
$29.25 M |
$35.43 M |
$64.54 M |
| Cost And Expenses |
$20.52 M |
$19.85 M |
$16.72 M |
$25.22 M |
$23.88 M |
$24.51 M |
$26.52 M |
$29.25 M |
$35.43 M |
$64.54 M |
| Interest Income |
$0.00 |
$651,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
-$14,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$2,000.00 |
| Depreciation &
Amortization |
$16,000.00
|
$14,000.00
|
-$321,000.00
|
$208,000.00
|
-$63,000.00
|
$55,000.00
|
$88,000.00
|
$96,000.00
|
$150,000.00
|
$434,000.00
|
| EBITDA |
-$20.28 M
|
-$19.63 M
|
-$16.82 M
|
-$24.79 M
|
-$21.76 M
|
-$24.88 M
|
-$27.37 M
|
-$27.66 M
|
-$23.82 M
|
-$63.71 M
|
| EBITDA Ratio |
-89.74 |
-86.85 |
-74.41 |
-107.29 |
-9.97 |
-20.26 |
-34.77 |
-4.99 |
-2.08 |
-79.64 |
| Operating Income Ratio
|
-89.81
|
-86.85
|
-72.99
|
-108.19
|
-9.94
|
-18.96
|
-32.7
|
-4.27
|
-2.09
|
-79.68
|
| Total Other
Income/Expenses Net |
$1.35 M
|
$663,000.00
|
$333,000.00
|
-$160,000.00
|
$206,000.00
|
$2.75 M
|
$1.66 M
|
$4.05 M
|
-$35,000.00
|
-$32,000.00
|
| Income Before Tax |
-$18.95 M |
-$18.96 M |
-$16.16 M |
-$25.15 M |
-$21.49 M |
-$20.53 M |
-$24.08 M |
-$19.65 M |
-$24.01 M |
-$63.78 M |
| Income Before Tax Ratio
|
-83.84
|
-83.91
|
-71.52
|
-108.89
|
-9.85
|
-16.72
|
-30.6
|
-3.54
|
-2.1
|
-79.72
|
| Income Tax Expense |
$0.00 |
-$663,000.00 |
-$335,000.00 |
$4,000.00 |
$10,000.00 |
-$124,000.00 |
$13,000.00 |
$14,000.00 |
$16,000.00 |
$19,000.00 |
| Net Income |
-$18.95 M |
-$18.30 M |
-$15.83 M |
-$25.16 M |
-$21.50 M |
-$20.57 M |
-$24.09 M |
-$19.67 M |
-$23.98 M |
-$63.68 M |
| Net Income Ratio |
-83.84 |
-80.98 |
-70.04 |
-108.9 |
-9.85 |
-16.75 |
-30.61 |
-3.55 |
-2.09 |
-79.6 |
| EPS |
-0.9 |
-0.88 |
-0.94 |
-2.17 |
-22.42 |
-53.37 |
-602.28 |
-999.64 |
-2372.75 |
-6617.69 |
| EPS Diluted |
-0.9 |
-0.88 |
-0.94 |
-2.17 |
-22.42 |
-53.37 |
-602.28 |
-999.64 |
-2372.75 |
-6617.69 |
| Weighted Average Shares
Out |
$20.99 M
|
$20.91 M
|
$16.83 M
|
$11.60 M
|
$958,965.00
|
$385,475.00
|
$40,001.00
|
$19,673.00
|
$10,106.00
|
$9,623.00
|
| Weighted Average Shares
Out Diluted |
$20.99 M
|
$20.91 M
|
$16.83 M
|
$11.60 M
|
$958,965.00
|
$385,476.00
|
$40,001.00
|
$19,674.00
|
$10,106.00
|
$9,623.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
